ASCO 2016 | Global differences in cancer drug prices: a comparative analysis

Daniel Goldstein

Press brief by Daniel Goldstein, MD of the Rabin Medical Center, Petah Tikva, Israel, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Share this video  
Similar topics
Related videos
0:48
The LUNAR study: TTFields for NSCLC
Ori Farber
0:55
Tumor treating fields as an anti-mitotic therapy
Ori Farber
0:48
Patient impact: development of drugs to treat METex14 alterations
Paul Paik
1:04
Tepotinib: advanced non-small cell lung cancer
Paul Paik
0:53
Future treatment options for squamous cell lung cancer
Paul Paik
Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Genitourinary Cancer, Gynecological Cancer, Gynecological Cancer, Lung Cancer, Skin Cancer
ASCO 2016
Press Brief
3rd June 2016
More from Daniel Goldstein
Is the current dose of pembrolizumab approved for treating lung cancer too high?
Personalized dosing of pembrolizumab has the potential to save $0.8 billion per year
Are physicians wasting healthcare resources by over-prescribing drugs?
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals